Pharsight

Afinitor patents expiration

AFINITOR's oppositions filed in EPO
AFINITOR Litigations
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(1 year, 7 months ago)

US8436010 NOVARTIS Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(1 year, 7 months ago)

US8778962

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 1 month ago)

US8436010

(Pediatric)

NOVARTIS Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 1 month ago)

US8410131 NOVARTIS Cancer treatment
Nov, 2025

(2 years from now)

US8410131

(Pediatric)

NOVARTIS Cancer treatment
May, 2026

(2 years from now)

US9006224 NOVARTIS Neuroendocrine tumor treatment
Jul, 2028

(4 years from now)

Afinitor is owned by Novartis.

Afinitor contains Everolimus.

Afinitor has a total of 7 drug patents out of which 4 drug patents have expired.

Expired drug patents of Afinitor are:

  • US8778962
  • US8436010
  • US8778962*PED
  • US8436010*PED

Afinitor was authorised for market use on 30 March, 2009.

Afinitor is available in tablet;oral dosage forms.

Afinitor can be used as treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic, treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib, treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected., treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.

The generics of Afinitor are possible to be released after 01 July, 2028.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2023

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 30 March, 2009

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic